REDX PHARMA PLC ( Redx or Company or Group ) Interim Results

Transcription

1 24 May 2016 AIM: REDX REDX PHARMA PLC ( Redx or Company or Group ) Interim Results Redx (AIM: REDX), the drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 31 March HIGHLIGHTS Continued strong progress across proprietary research programs Oncology pipeline - fourth development candidate selected Porcupine inhibitor for hard-to-treat cancers, such as pancreatic, triple negative breast and head and neck cancers - post period: in vivo proof of concept achieved in BTK program reversible inhibitor with potential to treat leukaemia and other blood cancers see separate announcement issued today Anti-infectives pipeline - proof of concept established with a lead compound which has the potential to treat gonorrhoea, one of the most common sexually transmitted infections globally Immunology pipeline - several projects have now been successfully initiated - currently conducting pre-clinical efficacy studies for treatment of an immunological disease with high unmet need H1 financial results in line with management expectations: - net cash at 31 March 2016: 4.4m (H1 2015: 13.8m) - comprehensive loss of 7.1m (H1 2015: 3.2m) Successful share placing to raise 10m (gross) completed in April, after period end Outlook remains positive and the Company remains well-positioned to secure value from its assets and to further develop the business Page 1 of 19

2 Neil Murray, Chief Executive of Redx Pharma Plc, said: I am pleased to report that interim results are in line with management expectations and that Redx s innovative pipeline has made excellent progress over the period. We identified a fourth drug development candidate, a Porcupine inhibitor, which has the potential to tackle hard-to-treat cancers, such as pancreatic, triple negative breast and head and neck cancers, reaching development stage in less than two years, significantly ahead of industry averages. Our anti-infectives team also achieved a further proof of concept, with a lead which has the potential to treat drug-resistant gonorrhoea. Today, we are delighted to announce our seventh proof of concept, a BTK reversible inhibitor that has the potential to treat leukaemia and other blood cancers. We completed a 10m fundraise shortly after the period ended, which leaves us well-positioned to build on our pipeline progress and grow the business. For further information, please contact: Redx Pharma Plc T: Neil Murray, Chief Executive Company website: redxpharma.com Cantor Fitzgerald Europe (Nomad & Broker) T: Phil Davies / Michael Reynolds KTZ Communications T: Katie Tzouliadis/ Viktoria Langley/ Emma Pearson Page 2 of 19

3 About Redx Pharma Plc Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of proprietary (patent-protected) drug programs. Seven proof of concepts have been achieved, with relevance for respective therapies to treat MRSA, Gonorrhoea, bone tumours, skin, brain, breast, pancreatic and blood cancers. Page 3 of 19

4 Page 4 of 19

5 which is an. Imbruvica TM (ibrutinib), Page 5 of 19

6 Page 6 of 19

7 Page 7 of 19

8 Page 8 of 19

9 Page 9 of 19

10 Page 10 of 19

11 Page 11 of 19

12 Page 12 of 19

13 Page 13 of 19

14 Page 14 of 19

15 Page 15 of 19

16 Page 16 of 19

17 Page 17 of 19

18 Page 18 of 19

19 Page 19 of 19